Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Diabetes

Which risk engines should be used to assess patients with diabetes?

Nature Reviews Endocrinology volume 5, pages 302–303 (2009)Cite this article

The incidence of type 2 diabetes mellitus is rising, which increases the demand for cardiovascular prevention treatments. This situation raises an important question: should all individuals with this disorder be considered to have a high risk of cardiovascular events and be treated with preventative therapy, such as statins, or should risk-prediction regimens be used to guide therapy?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Evans, J. M., Wang, J. & Morris, A. D. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ 324, 939–942 (2002).

    Article  Google Scholar 

  2. Ruggenenti, P. et al. Preventing microalbuminuria in type 2 diabetes. N. Engl. J. Med. 351, 1941–1951 (2004).

    Article  CAS  Google Scholar 

  3. Kahn, S. E. et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355, 2427–2443 (2006).

    Article  CAS  Google Scholar 

  4. Buse, J. B. et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 115, 114–126 (2007).

    Article  Google Scholar 

  5. Price, H. C., Coleman, R. L., Stevens, R. J. & Holman, R. R. Impact of using a non-diabetes-specific risk calculator on eligibility for statin therapy in type 2 diabetes. Diabetologia 52, 394–397 (2009).

    Article  CAS  Google Scholar 

  6. Grundy, S. M. et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110, 227–239 (2004).

    Article  Google Scholar 

  7. Simmons, R. K. et al. Performance of the UK Prospective Diabetes Study Risk Engine and the Framingham Risk Equations in estimating cardiovascular disease in the EPIC–Norfolk cohort. Diabetes Care 32, 708–713 (2009).

    Article  Google Scholar 

  8. Emerging Risk Factors Collaboration et al. The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur. J. Epidemiol. 22, 839–869 (2007).

Download references

Author information

Authors and Affiliations

  1. Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK

    Kausik K. Ray

  2. British Heart Foundation, Glasgow Cardiovascular Research Center, Faculty of Medicine, University of Glasgow, Glasgow, UK

    Naveed Sattar

Authors
  1. Kausik K. Ray
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naveed Sattar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kausik K. Ray.

Ethics declarations

Competing interests

K. K. Ray declares an association with the following company: Novartis (speakers bureau). N. Sattar declares associations (consultant or advisory board) with the following companies: Merck, GlaxoSmithKline, Novo Nordisk and MSD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ray, K., Sattar, N. Which risk engines should be used to assess patients with diabetes?. Nat Rev Endocrinol 5, 302–303 (2009). https://doi.org/10.1038/nrendo.2009.100

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2009.100

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing